Cryotherapy is the application of extreme cold to freeze and destroy tumors and has proven to be an effective and minimally invasive technology that results in minimal pain, rapid recovery and high quality of life for patients.
Galil Medical, a global leader in minimally invasive cryotherapy cancer treatments, today announced that Vanderbilt University Medical Center in Nashville, Tenn., has treated the first patient to be included in its new patient registry.
Women's health leaders today called on the international community to commit the resources needed to ensure that women and girls worldwide have equal access to cervical cancer prevention technologies. At the WOMEN DELIVER conference, the Declaration for Universal Access to Cervical Cancer Prevention was issued by leading women's health, cancer and business organizations, including PATH, the International Planned Parenthood Federation and the International Union Against Cancer.
Scientists have shown that through eye examinations, doctors can identify infants who are most likely to benefit from early treatment for a potentially blinding eye condition called retinopathy of prematurity, resulting in better vision for many children.
Renal cell carcinoma accounts for about 3% of all solid tumours in adults, and worldwide, more than 200.000 new cases and 100.000 deaths result each year from this malignancy.
Revolutionary new CryoSTAT is here to put the fire out when it comes to hemorrhoids by treating them on contact with cold therapy which has a proven track record of providing instant relief with no mess.
Renal cell carcinoma (RCC) accounts for about 3% of all solid tumours in adults, and worldwide, more than 200.000 new cases and 100.000 deaths result each year from this malignancy.
Surgeons at the University of California, San Diego School of Medicine report what is believed to be the nation's first single-incision laparoscopy to perform a combined colectomy and kidney-preserving therapy.
Cryotherapy, an interventional radiology treatment to freeze cancer tumors, may become the treatment of the future for cancer that has metastasized in soft tissues (such as ovarian cancer) and in bone tumors.
Interventional radiologists have opened the door to an encouraging potential future treatment for the nearly 200,000 women who are diagnosed with breast cancer in the United States each year: image-guided, multiprobe cryotherapy.
Specialty pharmaceutical company LEO Pharma today announced that findings from a Phase III study evaluating PEP005 (ingenol mebutate) Gel 0.05% to treat actinic keratosis (AK), a common pre-cursor to skin cancer, were presented at the 68th Annual Meeting of the American Academy of Dermatology (AAD) (Scientific Session Poster Discussion: P105). Results from REGION-I demonstrated treatment with PEP005 Gel once daily for 2 consecutive days.
Acculis Limited today announced the regulatory clearance of its revolutionary new device for destroying unwanted tissues, such as liver tumours. The clearance under the European CE Mark system allows the company to begin deliveries for treating patients throughout Europe and elsewhere where the CE Mark system is recognised. The device is a single high power high frequency 2.45GHz microwave needle that burns a 5cm sphere of tissue in just 5 minutes which is between 3 to 10 times faster than old school radiofrequency based systems or lower frequency 915MHz microwave systems.
LEO Pharma today announced that in a Phase III study, PEP005 (ingenol mebutate) Gel, the company's lead candidate for the topical treatment of actinic (solar) keratosis (AK) or pre-cancerous lesions, met its primary clinical endpoint of complete clearance of AK lesions in non-head locations.
PhotoMedex and Galderma Laboratories, L.P. have entered into a co-promotion agreement for Galderma’s photodynamic therapy application for the treatment of actinic keratoses (“AK”).
According to a new global report series by iData Research, the leading authority in medical device, dental and pharmaceutical market research, the U.S. market for urological devices is estimated to more than double in value by 2016, reaching over $5.4 billion.
Health Canada has approved Zyclara™ (imiquimod) Cream 3.75%, a topical prescription treatment for multiple actinic keratoses (AK) located on the face or balding scalp in adults. Actinic Keratosis is a common skin condition that can lead to squamous cell carcinoma, a form of non-melanoma skin cancer, if left untreated.
Registration is now open for the Society of Interventional Radiology's "Image-guided Interventional Oncology (IO) Therapies" Webinar, which will provide the latest updates on percutaneous and transcatheter treatment of liver tumors, kidney tumor ablation and lung tumor ablation.
Sangretech Biomedical LLC, a developer of dendritic cell therapies for cancer and infectious diseases, today announced it has executed an amended and restated license agreement with Bostwick Laboratories, Inc. providing Bostwick Scientific, the research division of Bostwick Laboratories, with exclusive rights to Sangretech’s dendritic cell technology in certain territories.
The Medical Design Excellence Awards (MDEA) program is accepting entries for its 2010 competition from companies and individuals worldwide involved in the design, engineering, manufacture, or distribution of finished medical devices or packaging products.
Long-term risks of invasive cancer and recurrence of severe cervical intraepithelial neoplasia (CIN) are higher among women previously treated for CIN, compared with those with no CIN diagnosis, according to data from a large, retrospective cohort study published in the May 12 online issue of the Journal of the National Cancer Institute
The American Urological Association (AUA) today issued new clinical guidance - which directly contrasts recent recommendations issued by other major groups - about prostate cancer screening, asserting that the prostate-specific antigen (PSA) test should be offered to well-informed, men aged 40 years or older who have a life expectancy of at least 10 years.